Who
Laurence Marton
Director
Company insider
Files Form 4 as: Director, RenovoRx; Director, Matternet.
In numbers
- Trades disclosed
- 22
- Buys
- 3
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Oct 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,924 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | Matternetoption or derivative | SEC FORM 4 Code A | —266,488 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | Matternetoption or derivative | SEC FORM 4 Code A | —181,898 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | Matternetoption or derivative | SEC FORM 4 Code A | —41,602 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | Matternet | SEC FORM 4 Code A | —52,003 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —9,720 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,860 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,860 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —9,720 | filing |
| 1 Oct 2025filed 3 Oct 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,640 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,480 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code M | $3,07220,480 at $0.15 | filing |
| 8 Apr 2025filed 9 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $10K12,050 at $0.85 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —8,196 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —8,196 | filing |
| 1 Oct 2023filed 2 Oct 2023 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 3 Nov 2022filed 4 Nov 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,438 at $0.00 | filing |
| 3 Nov 2022filed 4 Nov 2022 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code M | $43K25,438 at $1.70 | filing |
| 1 Oct 2022filed 4 Oct 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
News
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialRNXT · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Laurence Marton; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.